Transcend Capital Advisors’s TG Therapeutics TGTX Stock Holding History

Transcend Capital Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$476K	Buy	8,658 +157	+2%	+$6.42K	0.03%	476
2026 Q1	$282K	Buy	8,501 +17	+0.2%	+$507	0.02%	564
2025 Q4	$253K	Hold	8,484	–	–	0.02%	580
2025 Q3	$306K	Sell	8,484 -855	-9%	-$28.2K	0.02%	525
2025 Q2	$336K	Sell	9,339 -2	-0%	-$74	0.03%	428
2025 Q1	$368K	Buy	9,341 +2	+0%	+$67	0.03%	427
2024 Q4	$281K	Buy	9,339 +22	+0.2%	+$631	0.02%	456
2024 Q3	$218K	Buy	+9,317	New	+$203K	0.01%	556

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Transcend Capital Advisors's TGTX Position: Q2 2026 in Review

Transcend Capital Advisors increased its TG Therapeutics (TGTX) stake by 1.8% in Q2 2026, buying an estimated $6.42K and bringing the position to 8,658 shares worth $476K. The position accounts for 0.03% of the portfolio, ranked #476.

Transcend Capital Advisors first reported a position in TGTX in Q3 2024 and has held it in 8 quarters since. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Transcend Capital Advisors held 8,658 shares of TG Therapeutics worth $476K as of Q2 2026.
Transcend Capital Advisors bought 157 TG Therapeutics shares in Q2 2026, an estimated $6.42K.
TG Therapeutics made up 0.03% of Transcend Capital Advisors's portfolio in Q2 2026, its #476 holding.
Transcend Capital Advisors first reported a position in TG Therapeutics in Q3 2024 and has held it in 8 quarters since.
431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Transcend Capital Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.